Skip to content


Evkeeza (evinacumab) is an antibody pharmaceutical. Evinacumab was first approved as Evkeeza on 2021-02-11. It has been approved in Europe to treat hypercholesterolemia. The pharmaceutical is active against angiopoietin-related protein 3.
Trade Name Evkeeza
Common Name Evinacumab
Indication hypercholesterolemia
Drug Class Monoclonal antibodies: fully human, cardiovascular indications; vinca alkaloids
Get full access now